

May 31, 2024

## **Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL)** **US-Approved Product – Now Available**

Dear Valued Customer,

To help mitigate a drug shortage situation in Canada, Health Canada has permitted the importation and release of **Fresenius Kabi's US-approved Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL)**.

Healthcare professionals should note that there are differences between the currently approved Canadian product and the product being supplied. Please refer to the following important information:

1. Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL) - Canadian Product Monograph for prescribing information.
2. Health Product Risk Communication (HPRC) dated May 31, 2024 describing details and differences between the Canadian– and the US-approved Moxifloxacin Injection products.

The HPRC and product monograph can be conveniently located on the Fresenius Kabi website at <https://www.fresenius-kabi.com/en-ca/> in addition to the Health Canada website.

Please note that this product will be available on allocation and will be accessible as of June 3, 2024. Contract customers will be allocated **100% of historical monthly demand**.

<b>Fresenius Kabi Product Code</b>	<b>MDP Product Code</b>	<b>McKesson Product Code</b>	<b>Product Description</b>	<b>Pack Size</b>	<b>Availability Date</b>
850174	978413	190875	Fresenius Kabi's US-approved Moxifloxacin Injection, 400 mg per 250 mL (1.6 mg per mL)	12 units per pack*	Jun. 3, 2024 100% allocation

\*Please be advised that this pack factor is different than our approved Canadian product, which is supplied in packs of 10 units.

If you have any questions or for more information, please contact your Sales Representative or our Customer Service Department at: [Canada\\_CustomerService@Fresenius-Kabi.com](mailto:Canada_CustomerService@Fresenius-Kabi.com) or (877) 821-7724.

Sincerely,



Joseph Le  
Associate Director, IV Drugs  
[joseph.le@fresenius-kabi.com](mailto:joseph.le@fresenius-kabi.com)



Scan and register to receive our communications via email.